LV10432B - Neuromuscular transmission blocators - Google Patents

Neuromuscular transmission blocators Download PDF

Info

Publication number
LV10432B
LV10432B LVP-92-334A LV920334A LV10432B LV 10432 B LV10432 B LV 10432B LV 920334 A LV920334 A LV 920334A LV 10432 B LV10432 B LV 10432B
Authority
LV
Latvia
Prior art keywords
cis
atracurium
umc
salt
physiologically acceptable
Prior art date
Application number
LVP-92-334A
Other languages
English (en)
Latvian (lv)
Other versions
LV10432A (lv
Inventor
Hill Derek Anthony
Turner Geoffrey Lloyd
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of LV10432A publication Critical patent/LV10432A/xx
Publication of LV10432B publication Critical patent/LV10432B/lv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18Aralkyl radicals
    • C07D217/20Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Semiconductor Lasers (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Led Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Paper (AREA)
LVP-92-334A 1990-07-13 1992-12-18 Neuromuscular transmission blocators LV10432B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909015473A GB9015473D0 (en) 1990-07-13 1990-07-13 Neuromuscular blocking agents
PCT/GB1991/001150 WO1992000965A1 (en) 1990-07-13 1991-07-12 Neuromuscular blocking agents

Publications (2)

Publication Number Publication Date
LV10432A LV10432A (lv) 1995-02-20
LV10432B true LV10432B (en) 1995-08-20

Family

ID=10679071

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-92-334A LV10432B (en) 1990-07-13 1992-12-18 Neuromuscular transmission blocators

Country Status (40)

Country Link
EP (1) EP0539470B1 (de)
JP (3) JP2823356B2 (de)
KR (1) KR0174284B1 (de)
AT (1) ATE138369T1 (de)
AU (2) AU8190491A (de)
BE (1) BE1003407A3 (de)
CA (1) CA2087104C (de)
CH (1) CH683427A5 (de)
CY (1) CY1985A (de)
CZ (1) CZ284645B6 (de)
DE (2) DE69119768T2 (de)
DK (2) DK0539470T3 (de)
ES (2) ES2083315B1 (de)
FI (2) FI982342L (de)
FR (1) FR2665701B1 (de)
GB (2) GB9015473D0 (de)
GE (1) GEP19981163B (de)
GR (1) GR3020792T3 (de)
HK (1) HK80196A (de)
HU (2) HU218766B (de)
IE (1) IE912440A1 (de)
IL (1) IL98814A (de)
IT (1) IT1249677B (de)
LT (1) LT3317B (de)
LU (1) LU88198A1 (de)
LV (1) LV10432B (de)
MX (1) MX9203220A (de)
MY (1) MY113017A (de)
NL (1) NL9120017A (de)
NZ (1) NZ238964A (de)
PA (1) PA8401801A1 (de)
PL (1) PL167302B1 (de)
PT (1) PT98306B (de)
RU (1) RU2104005C1 (de)
SA (1) SA91120073B1 (de)
SE (1) SE9300052D0 (de)
SK (1) SK279907B6 (de)
UA (1) UA32536C2 (de)
WO (1) WO1992000965A1 (de)
ZA (1) ZA915468B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453510A (en) * 1990-07-13 1995-09-26 Burroughs Wellcome Co. Neuromuscular blocking agents
DE19535762A1 (de) * 1995-09-26 1997-03-27 Basf Ag Verfahren zur Racematspaltung
US5684154A (en) * 1996-02-16 1997-11-04 Abbott Laboratories Process for the preparation and isolation of atracurium besylate
DE69830157T2 (de) * 1997-03-25 2006-05-11 Avera Pharmaceuticals, Inc., San Diego Substituierte isochinoline als ultrakurz wirkende neuromuskuläre blocker
AU2008222298A1 (en) 2007-03-08 2008-09-12 Chemagis Ltd. (1R,1'R)-atracurium salts separation process
WO2008117271A1 (en) * 2007-03-26 2008-10-02 Chemagis Ltd. (1r,1'r)-atracurium salts separation process
AU2008273724B2 (en) 2007-05-01 2013-05-23 Chemagis Ltd. Process for Producing Cisatracurium and Associated Intermediates
WO2008132748A1 (en) 2007-05-01 2008-11-06 Chemagis Ltd. Process for producing cisatracurium compounds and associated intermediates
AU2008264802A1 (en) * 2007-06-18 2008-12-24 Chemagis Ltd. (1R,1'R)-atracurium salts separation process
CN101337936B (zh) * 2007-07-06 2011-03-23 江苏恒瑞医药股份有限公司 一种用柱色谱法纯化苯磺酸阿曲库铵的方法
CN101337935B (zh) * 2007-07-06 2011-01-12 江苏恒瑞医药股份有限公司 一种用两相萃取法纯化苯磺酸阿曲库铵的方法
WO2009057086A1 (en) 2007-10-29 2009-05-07 Chemagis Ltd. Novel r,r'-atracurium salts
IT1396543B1 (it) * 2008-07-16 2012-12-14 Farmabios Spa Processo per la purificazione di bloccanti neuromuscolari
WO2010128518A2 (en) * 2009-05-04 2010-11-11 Gland Pharma Limited Novel process for the preparation of cisatracurium besylate
CN107056700A (zh) * 2017-04-18 2017-08-18 哈尔滨医科大学 一种四氢异喹啉类化合物外消旋体的半量拆分法
CN112939862B (zh) * 2021-02-03 2023-01-10 江苏诚信药业有限公司 一种苯磺顺阿曲库铵杂质h的分离制备方法及其应用
CN115850169B (zh) * 2022-10-17 2025-04-04 上海医药集团(本溪)北方药业有限公司 苯磺顺阿曲库铵杂质及其中间体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3004031A (en) * 1958-07-03 1961-10-10 Allen & Hauburys Ltd Diquaternary salts of papaverino esters
AU506657B2 (en) * 1975-12-10 1980-01-17 Wellcome Foundation Limited, The Isoquinoline derivatives
GB1579822A (en) * 1976-10-29 1980-11-26 Wellcome Found Tetrahydroisoquinolinium muscle relaxants
ES454090A1 (es) * 1976-12-09 1978-01-16 Wellcome Found Un metodo para preparar compuestos heterociclicos.
DE3328664A1 (de) * 1983-08-09 1985-02-21 Robert Bosch Gmbh, 7000 Stuttgart Zuckerziehmaschine
BG41897A1 (en) * 1985-07-19 1987-09-15 Ivanov Dichlormethylate of n, n'- 4, 10- dioxa- 3, 11- bis- tetrahydropapaverine and method for its preparation
US9524531B2 (en) 2011-05-09 2016-12-20 Microsoft Technology Licensing, Llc Extensibility features for electronic communications

Also Published As

Publication number Publication date
WO1992000965A1 (en) 1992-01-23
SA91120073B1 (ar) 2002-10-26
EP0539470A1 (de) 1993-05-05
LTIP274A (en) 1994-10-25
DE69119768D1 (de) 1996-06-27
HU218766B (hu) 2000-11-28
FI982342A0 (fi) 1998-10-28
AU687481B2 (en) 1998-02-26
UA32536C2 (uk) 2001-02-15
EP0539470B1 (de) 1996-05-22
NZ238964A (en) 1992-06-25
MX9203220A (es) 1992-07-01
ES2083315B1 (es) 1997-11-16
SK383392A3 (en) 1999-05-07
IT1249677B (it) 1995-03-09
ATE138369T1 (de) 1996-06-15
GB9224764D0 (en) 1993-02-03
IL98814A (en) 1995-12-08
JPH05508648A (ja) 1993-12-02
FI103507B (fi) 1999-07-15
PT98306A (pt) 1992-06-30
DK149692D0 (da) 1992-12-14
GB9015473D0 (en) 1990-08-29
BE1003407A3 (fr) 1992-03-17
PA8401801A1 (es) 1997-01-03
SE9300052L (sv) 1993-01-12
PT98306B (pt) 1999-01-29
GR3020792T3 (en) 1996-11-30
FR2665701A1 (fr) 1992-02-14
HU211169A9 (en) 1995-11-28
CY1985A (en) 1997-09-05
JPH10139763A (ja) 1998-05-26
CH683427A5 (fr) 1994-03-15
FI982342A7 (fi) 1998-10-28
ES2088009T3 (es) 1996-08-01
FI925894A0 (fi) 1992-12-28
JP3462165B2 (ja) 2003-11-05
GB2260763A (en) 1993-04-28
AU1134695A (en) 1995-03-30
KR0174284B1 (ko) 1999-02-18
DE4191541T1 (de) 1993-05-13
MY113017A (en) 2001-11-30
JP2001058981A (ja) 2001-03-06
NL9120017A (nl) 1993-04-01
ITRM910518A1 (it) 1993-01-12
DK149692A (da) 1992-12-14
DE69119768T2 (de) 1996-10-02
HK80196A (en) 1996-05-17
SE9300052D0 (sv) 1993-01-12
JP2823356B2 (ja) 1998-11-11
RU2104005C1 (ru) 1998-02-10
GB2260763B (en) 1994-01-05
HU9300052D0 (en) 1993-04-28
SK279907B6 (sk) 1999-05-07
ITRM910518A0 (it) 1991-07-12
HUT67613A (en) 1995-04-28
PL167302B1 (en) 1995-08-31
LV10432A (lv) 1995-02-20
ES2083315A1 (es) 1996-04-01
AU8190491A (en) 1992-02-04
IE912440A1 (en) 1992-01-15
DK0539470T3 (da) 1996-08-05
FR2665701B1 (fr) 1995-03-03
LU88198A1 (fr) 1993-05-17
LT3317B (en) 1995-06-26
ZA915468B (en) 1993-03-31
PL297606A1 (de) 1992-07-13
CZ284645B6 (cs) 1999-01-13
IL98814A0 (en) 1992-07-15
FI103507B1 (fi) 1999-07-15
FI982342L (fi) 1998-10-28
CA2087104A1 (en) 1992-01-14
FI925894L (fi) 1992-12-28
CZ383392A3 (en) 1994-02-16
CA2087104C (en) 1998-08-18
GEP19981163B (en) 1998-07-06

Similar Documents

Publication Publication Date Title
LV10432B (en) Neuromuscular transmission blocators
ES2197201T3 (es) Tratamiento de la neuritis optica.
de Leuw et al. Protease inhibitors for the treatment of hepatitis C virus infection
Mowat et al. Spontaneous bacterial peritonitis—diagnosis, treatment and prevention
Bicart-Sée et al. Successful treatment with nitazoxanide of Enterocytozoon bieneusi microsporidiosis in a patient with AIDS
Ben-Abraham et al. ‘Ecstasy’intoxication: life-threatening manifestations and resuscitative measures in the intensive care setting
Gokhale et al. Use of barbiturates in the treatment of cyclic vomiting during childhood
Fu et al. Clinical analysis of patients suffering from chronic hepatitis B superinfected with other hepadnaviruses
Lee et al. Ascites and spontaneous bacterial peritonitis: an Asian perspective
Uchida et al. Development of rare resistance‐associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two‐hit mechanism
Tsutsumi et al. The treatment of neuroleptic malignant syndrome using dantrolene sodium
EP0307176A3 (de) Erythromycin-Derivate
Paladini et al. Prenatal ultrasound diagnosis of Nager syndrome
Martín et al. Bascule syndrome associated with syncopal episodes
Cordova et al. Poor response to desmopressin acetate (DDAVP) in children with Hermansky–Pudlak syndrome
Calista et al. Erythema nodosum induced by kerion celsi of the scalp
Ferrándiz‐Pulido et al. Secondary syphilis with liver involvement in a liver transplant recipient
Hussain et al. Maternal methadone may cause arrhythmias in neonates
Aminiahidashti et al. Recurrent seizures after lidocaine ingestion
Patrao et al. Diffuse cutaneous leishmaniasis in coexistence with leprosy
Barr Jr et al. Autosomal recessive alobar holoprosencephaly with essentially normal faces
CA2181901A1 (en) Pyridazinone derivatives
Ota et al. An atypical case of atypical pneumonia
Ausloos et al. N-butyl-2-cyanoacrylate in gastric varices: a cause for recurrent sepsis
Germain Co‐occurrence and contribution of Fabry disease and Klippel–Trénaunay–Weber syndrome to a patient with atypical skin lesions